Caesarstone Hit With $67.3M Silicosis Jury Verdict; 69.1% Fault Share Equals ~$46.5M
CSTE has more than doubled off its 52-week low of $0.558 on light trading volume (0.3× avg).
Summary
A California jury found Caesarstone liable in a silicosis case and awarded about $67.3 million, with the company's 69.1% fault share equating to roughly $46.5 million if assessed without modification. The company is weighing post-trial remedies and appeal.
Key Events · Legal and Risk Events · CSTE
-
Jury Returns $67.3M Silicosis Verdict
On October 26, 2026, a Los Angeles Superior Court jury found Caesarstone liable in Dennys Rene Rivas-Williams v. A&A Granite Marble, et al. (Case No. 23STCV08523), part of the coordinated silicosis proceeding JCCP 5378, and awarded the plaintiff approximately $67.3 million.
-
Company's Share of Fault ~$46.5M
Caesarstone was apportioned 69.1% of the fault, or approximately $46.5 million if assessed without modification — a figure equal to more than half the company's ~$81 million market value.
-
Appeal and Financing Options Under Review
The company said it is considering its available actions; its forward-looking statement references post-trial remedies, an appeal, the ultimate outcome of the case and other pending claims, and its ability to obtain additional financing.
-
One Case in Broader Silicosis Docket
The verdict is one of multiple lawsuits alleging fabricators contracted illnesses, including silicosis, from exposure to silica while fabricating the company's products, so exposure extends beyond this single plaintiff.
Analysis · CSTE · Manufacturing
A Los Angeles jury found Caesarstone liable in a silicosis case and awarded the plaintiff about $67.3 million, with the company apportioned 69.1% of fault — roughly $46.5 million if assessed without modification. That verdict exceeds half the equity of a company with a market value of roughly $81 million, and it lands on top of an already weak demand backdrop: Q2 revenue fell 4.5% to $96.6M and new U.S. tariffs on quartz imports took effect August 1. The company says it is considering its available actions, and the filing's own forward-looking language references post-trial remedies, an appeal, and its ability to obtain additional financing — so the verdict is not yet a final cash obligation, but it materially raises the risk of a large payout or a capital raise. Because this is one case within the coordinated JCCP 5378 silicosis proceeding, the read-through to other pending claims is the core issue for the thesis.
How filings like this one have moved
In the 30 days to Oct 29, 2026, 48.1% of the 237 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -1.09%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CSTE was trading at $2.37 on NASDAQ in the Manufacturing sector, with a market capitalization of approximately $81.3M. The 52-week trading range was $0.56 to $3.84. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.